Rozrolimupab

DB05209InvestigationalProtein Based Therapies

Rozrolimupab is a recombinant polyclonal antibody consisting of 25 different anti-Rhesus D (RhD) antibodies to replace existing anti-RhD hyperimmune immunoglobulins for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) and the...

Mechanism: Pharmacologically active on Blood group Rh(D) polypeptide
Curator reviewed
Primary indication: Investigated for use/treatment in thrombocytopenia.Curator reviewed
Also known as: Recombinant human antigen-specific polyclonal antibody (pAb) against RhD antigen expressed in Chinese hamster ovary cells
Code names: SYM-001

Resolves to

Compound

UNIIS134V96RPQCAS909402-77-3

Targets

Q02161RHDA6PZ59RHD

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rozrolimupab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account